SEARCH

SEARCH BY CITATION

References

  • 1
    Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893917.
  • 2
    Gomaa AI, Khan SA, Toledano MB et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14: 43008.
  • 3
    Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15 (Suppl 4): 513.
  • 4
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 5
    Kim BK, Han KH, Ahn SH. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology 2011; 81 (Suppl 1): 419.
  • 6
    McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15: 22343, vii–x.
  • 7
    Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 8092.
  • 8
    Zhang CY, Huang TR, Yu JH et al. Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China. Chin J Cancer 2010; 29: 54550.
  • 9
    Yu MW, Chang HC, Chen PJ et al. Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 2002; 31: 100815.
  • 10
    Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 194256.
  • 11
    Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010; 52: 2527.
  • 12
    Khoury MJ, Beaty TH, Liang KY. Can familial aggregation of disease be explained by familial aggregation of environmental risk factors? Am J Epidemiol 1988; 127: 67483.
  • 13
    Gong HM. [Family aggregation of hepatocarcinoma–preliminary analysis.] Zhonghua Zhong Liu Za Zhi 1985; 7: 40810. (In Chinese.)
  • 14
    Yu MW, Chang HC, Liaw YF et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000; 92: 115964.
  • 15
    Hassan MM, Spitz MR, Thomas MB et al. The association of family history of liver cancer with hepatocellular carcinoma: a case–control study in the United States. J Hepatol 2009; 50: 33441.
  • 16
    Gao Y, Jiang Q, Zhou X et al. HBV infection and familial aggregation of liver cancer: an analysis of case–control family study. Cancer Causes Control 2004; 15: 84550.
  • 17
    Qiao B, Wang J, Xie J et al. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med 2012; 29: 83240.
  • 18
    Wu FX, Wang Q, Zhang ZM et al. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy. Cancer Lett 2009; 279: 16370.
  • 19
    Qiu JG, Fan J, Liu YK et al. Screening and detection of portal vein tumor thrombi-associated serum low molecular weight protein biomarkers in human hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 299305.
  • 20
    Pan J, Sun LC, Tao YF et al. ATP synthase ecto-alpha-subunit: a novel therapeutic target for breast cancer. J Transl Med 2011; 9: 211.
  • 21
    Gatlin-Bunai CL, Cazares LH, Cooke WE et al. Optimization of MALDI-TOF MS detection for enhanced sensitivity of affinity-captured proteins spanning a 100 kDa mass range. J Proteome Res 2007; 6: 451724.
  • 22
    Callesen AK, Christensen R, Madsen JS et al. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 291300.
  • 23
    Tirumalai RS, Chan KC, Prieto DA et al. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096103.
  • 24
    Tai DI, Changchien CS, Hung CS, Chen CJ. Replication of hepatitis B virus in first-degree relatives of patients with hepatocellular carcinoma. Am J Trop Med Hyg 1999; 61: 7169.
  • 25
    Zinkin NT, Grall F, Bhaskar K et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008; 14: 4707.
  • 26
    Junrong T, Huancheng Z, Feng H et al. Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma. J Biosci 2011; 36: 65968.
  • 27
    Pleguezuelo M, Lopez-Sanchez LM, Rodriguez-Ariza A et al. Proteomic analysis for developing new biomarkers of hepatocellular carcinoma. World J Hepatol 2010; 2: 12735.
  • 28
    Jiang ZH, Zhang ZY, He M et al. [The screening and identification of Apolipoprotein A-II from serum differential proteins in hepatocellular carcinoma patients.] Zhonghua Gan Zang Bing Za Zhi 2010; 18: 4459. (In Chinese.)
  • 29
    Blanc JF, Lalanne C, Plomion C et al. Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics 2005; 5: 377889.
  • 30
    Yokoyama Y, Kuramitsu Y, Takashima M et al. Protein level of apolipoprotein E increased in human hepatocellular carcinoma. Int J Oncol 2006; 28: 62531.
  • 31
    Lichtor T. Gene expression of apolipoprotein E in human brain tumors. Neurosci Lett 1992; 138: 28790.
  • 32
    Hough CD, Sherman-Baust CA, Pizer ES et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 2000; 60: 62817.
  • 33
    Zhang HL, Wu J, Zhu J. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Dev Immunol 2010; 2010: doi: 10.1155/2010/186813.
  • 34
    Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011; 53: 46774.
  • 35
    He QY, Zhu R, Lei T et al. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. J Cell Biochem 2008; 103: 74052.
  • 36
    Sung HJ, Ahn JM, Yoon YH et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 2011; 10: 138395.
  • 37
    Vermaat JS, Gerritse FL, van der Veldt AA et al. Validation of Serum Amyloid alpha as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol 2012; doi: 10.1016/j.eururo.2012.01.020.
  • 38
    Urieli-Shoval S, Finci-Yeheskel Z, Dishon S et al. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem 2010; 58: 101523.
  • 39
    Li J, Xie Z, Shi L et al. Purification, identification and profiling of serum amyloid A proteins from sera of advanced-stage cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 890: 39.